A supplement and a medicine can contain the same molecule, come in the same capsule, and sit on shelves two metres apart. What separates them in the European Union is not strength, quality or seriousness. It is a legal definition, and it turns on two things: what the product is presented as, and what it actually does to the body.
The short answer
In EU law a food supplement is a food. Directive 2002/46/EC defines it as a foodstuff whose purpose is to supplement the normal diet, a concentrated source of nutrients or other substances with a nutritional or physiological effect, sold in dose form such as capsules, tablets, sachets or drops.
A medicinal product is defined separately, in Directive 2001/83/EC, and it has two independent definitions. A product is a medicine if it is presented as having properties for treating or preventing disease. It is also a medicine if it may be used with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis. Either one is enough.
So the boundary is not a strength ladder with supplements at the bottom and medicines at the top. They are two categories with two definitions, and a product crosses over the moment it satisfies one of the medicine definitions. That is also why food law itself steps aside: Regulation (EC) No 178/2002, the general food law, defines food and then explicitly excludes medicinal products from that definition.
Door one: what you say about a product can change what it legally is
The first definition in Directive 2001/83/EC is about presentation. If a product is presented as having properties for treating or preventing disease in human beings, it is a medicinal product, regardless of what is inside it. A herbal tea claimed to cure an infection is a medicine by presentation. The same tea sold as a warm drink is food.
This is the definition that reaches marketing copy, packaging, brochures, websites and, in practice, the things a brand says on social media. It exists to protect people from products that do not have the effect they are led to expect.
It has a limit, though. In its 2007 judgment in Case C-319/05, the Court of Justice was clear that a capsule is not a confession. It held that the capsule form is not exclusive to medicinal products, because a large number of foodstuffs are offered for sale in that form simply to make them easier to swallow, and that this evidence alone is not sufficient to confer the status of medicinal product by presentation.
The practical reading: dose form does not make a medicine, and disease language does.
Door two: the effect has to be significant, not merely real
The second definition is about function, and this is where most of the argument happens. Almost every nutrient modifies a physiological function in some sense. If that were enough, half the supermarket would be a pharmacy.
The Court closed that gap. In Case C-319/05, Germany had classified a garlic preparation in capsule form as a medicinal product. The Court noted that the physiological effects relied on could also be obtained by ingesting 7.4 g of garlic as a foodstuff, that the product had no additional effects compared with eating garlic in its natural state, and that a product whose effect is no more than that of a foodstuff consumed in a reasonable quantity does not have a significant effect on the metabolism. Germany was found to have failed its obligations under the free movement rules.
The same logic was sharpened in Case C-140/07 (Hecht-Pharma, 2009), where the Court held that the function criterion must not lead to classifying as medicines products that have an effect on the human body but do not significantly affect the metabolism and so do not strictly modify the way it functions.
The test, in plain language, is whether the product does something the diet could not do anyway, and whether it does it to a degree that counts. A magnesium capsule that delivers what a mineral-rich meal delivers is food. A compound that changes a physiological process in a way food does not is heading somewhere else.
The doubt rule: when both fit, the medicine rules apply
Article 2(2) of Directive 2001/83/EC contains a tie-breaker that surprises most people. In cases of doubt, where a product may fall within the definition of a medicinal product and within the definition of a product covered by other EU legislation, the provisions of the medicines directive apply.
That is a strong rule, and it is why supplement labels sound so careful. Ambiguity does not split the difference. It defaults to the stricter regime.
Hecht-Pharma also fenced that rule in. The Court ruled that the directive does not apply to a product for which it has not been scientifically established that it is a medicinal product by function. Doubt means genuine doubt on the evidence, not a regulator's hunch.
Why the same product can be a supplement in one country and a medicine in another
Classification is not decided once for the whole EU. In Joined Cases C-211/03 and others (2005), the Court confirmed that the competent national authority must decide case by case, taking account of all the characteristics of the product: its composition, its pharmacological properties as far as science can establish them, the manner in which it is used, the extent of its distribution, its familiarity to consumers and the risks its use may entail.
National authorities can weigh those factors differently, and they do. A 2021 review in Phytomedicine traced this for five widely used botanicals (St John's wort, valerian, ginkgo, ginseng and green tea) and found the same botanical products sold across the EU as herbal medicinal products, food supplements, cosmetics or medical devices, with the legal position varying between countries. The authors called it a failure of harmonisation and an urgent case for fixing.
Melatonin shows the split inside one substance. Regulation (EU) No 432/2012 authorises the food claim that melatonin contributes to the reduction of time taken to fall asleep, for a food containing 1 mg per quantified portion, and a jet lag claim at 0.5 mg. At the same time, Circadin, a prolonged-release melatonin product, is an authorised medicine in the European Union. Same molecule, two regimes, decided by dose, presentation and intended use.
Red yeast rice: the clearest line the EU has drawn
If you want one worked example of the boundary being drawn in public, it is monacolin K.
Red yeast rice is a traditional fermented food. It also contains monacolin K, which, as the Commission recorded when it legislated, is in its lactone form identical to lovastatin, an active substance in cholesterol-lowering medicines.
EFSA concluded that monacolins from red yeast rice used as food supplements were of significant safety concern at 10 mg per day, and noted individual cases of severe adverse reactions at intakes as low as 3 mg per day taken for between two weeks and one year, including rhabdomyolysis, hepatitis and skin disorders requiring hospitalisation. The Authority could not identify a daily intake that raises no concern.
Commission Regulation (EU) 2022/860 therefore prohibited the use of monacolins from red yeast rice at 3 mg or more per daily portion in food. The food category was not banned. The dose at which it starts behaving like a statin was.
That is the boundary in one product: a traditional food at one dose, a medicine's active substance at another.
What this means for the words on a supplement label
Once a product sits on the food side of the line, three things follow, and together they explain almost every odd sentence you have read on a supplement box.
- No disease language, at all. Article 6(2) of Directive 2002/46/EC states that the labelling, presentation and advertising must not attribute to food supplements the property of preventing, treating or curing a human disease, or refer to such properties. Not "may help with", not implied, not in a customer testimonial.
- Only pre-authorised health claims. Under Regulation (EC) No 1924/2006, a health claim is any claim that states, suggests or implies a relationship between a food or its constituents and health, and Article 10(1) prohibits health claims unless they are authorised and on the EU list. That is why supplement copy repeats stiff phrases such as "contributes to the reduction of tiredness and fatigue" instead of writing something more natural. The wording is the authorisation. A narrow exception exists for reduction of disease risk claims under Article 14, but those too must be individually authorised, and they must carry a statement that the disease has multiple risk factors.
- Fixed mandatory statements. Article 6(3) requires the categories of nutrients or substances, the portion recommended for daily consumption, a warning not to exceed that dose, a statement that supplements are not a substitute for a varied diet, and a statement to keep the product out of reach of young children. Those sentences are not brand caution. They are law.
We wrote a companion piece on which label words are legally defined and which are pure marketing, in which words on a supplement label are legally defined, and on how to read the percentage column in what %NRV actually means.
What the food side does not have to do
The other half of the honest answer is what a supplement is not required to prove. A medicine reaches the market through an authorisation that assesses quality, safety and efficacy for a stated indication. A food supplement does not go through that. It is placed on the market under general food law and the operator carries the responsibility for its safety and compliance, with member states running notification schemes.
There is a middle route for plants. The European Medicines Agency describes a traditional use registration under Article 16a(1) of Directive 2001/83/EC, where no new clinical trials are required provided sufficient safety data and plausible efficacy are shown, and where the product must have been in use for at least 30 years including at least 15 years within the EU. A herbal product is therefore not automatically a supplement. It can be a registered traditional herbal medicine, and that registration is a real regulatory status, not a marketing phrase.
None of this makes supplements lower quality. It means the burden of proof sits in a different place, which is exactly why documentation matters on the food side. We went through what a lab certificate can and cannot prove in what a certificate of analysis actually proves.
Where our own shelf sits, honestly
Our catalogue straddles the line on purpose, and the labels say so.
Most of what we sell is unambiguously food. Magnesium 7-in-1, the bioactive B-complex, zinc picolinate and creatine monohydrate carry the words "food supplement", the recommended daily portion, the do not exceed warning, the not a substitute for a varied diet line and the keep out of reach of children line, because Article 6(3) requires them. Their benefit sentences are quoted authorisations, not our sentences: magnesium contributes to normal muscle and nervous system function, creatine increases physical performance in successive bursts of short-term high-intensity exercise, zinc contributes to the normal function of the immune system.
Three items on our site are not food at all. Our methylene blue solution, lithium orotate and alpha-GPC are labelled, in our own words on the product pages, as not a food, not a food supplement and not a medicinal product, supplied as laboratory and research items and not intended for human consumption. That is not a disclaimer bolted on for safety. It is the classification. Those substances have no food status in the EU, so calling them supplements would be the exact mistake this article is about.
If you ever see us describe a supplement as treating, preventing or curing anything, that is an error worth writing to us about. Under Article 6(2) it would not be permitted, whether or not it were true.
Frequently asked questions
Is a food supplement just a weaker version of a medicine?
No. They are separate legal categories with separate definitions. A supplement is a food in dose form under Directive 2002/46/EC. A medicine is defined by presentation or by significant pharmacological, immunological or metabolic action under Directive 2001/83/EC. A high dose does not turn a supplement into a medicine, and a low dose does not turn a medicine into a food.
Why can a supplement label not simply say what a nutrient does?
Because Regulation (EC) No 1924/2006 prohibits health claims unless they have been authorised and added to the EU list, and the authorised wording is what may be used. Anything about preventing, treating or curing disease is separately forbidden on supplements by Article 6(2) of Directive 2002/46/EC.
Can something be a supplement in Spain and a medicine in Germany?
Yes, and it happens. Classification is a national decision made case by case on composition, pharmacological properties, manner of use, extent of distribution, consumer familiarity and risk, as the Court set out in Joined Cases C-211/03 and others. A 2021 review in Phytomedicine documented the same botanicals sold across the EU under different categories in different countries.
Does "pharmaceutical grade" or "lab-tested" mean a product is a medicine?
No. Neither phrase is a legal classification. Purity and testing describe how a material was made and checked. Classification depends on presentation and on physiological function. This is exactly why we renamed our own methylene blue listing to laboratory grade: the older wording suggested a status the product does not have.
If a product has a real effect, should it not be a medicine?
Not necessarily. The Court has held that an effect is not enough. In the garlic case the product's effects were no greater than eating a reasonable amount of garlic, and in Hecht-Pharma the Court said products that affect the body but do not significantly affect the metabolism should not be classified as medicines by function.
Are herbal products always food supplements?
No. The same plant can be sold as a food supplement, as a well established use herbal medicine, or as a registered traditional herbal medicinal product under Article 16a(1) of Directive 2001/83/EC, which requires at least 30 years of use including 15 years in the EU. Which one applies depends on the product, the claim and the country.
The Bottom Line
The line between a food supplement and a medicine in the EU is drawn twice: once through what a product claims, and once through what it measurably does. Claim disease and you are a medicine by presentation. Act on the body significantly beyond what food does and you are a medicine by function. In genuine doubt, the medicines rules win.
That is why supplement labels read the way they do, why the same substance can be food in one country and a prescription elsewhere, and why 3 mg of monacolin K per portion is now the difference between a fermented rice product and a statin dose. Reading a label with that boundary in mind tells you more about what a product is allowed to be than any word on the front of the box.
Sources
- Directive 2001/83/EC on the Community code relating to medicinal products for human use, consolidated text, Articles 1(2), 2(2) and 16a. European Union, 2001 (consolidated 2022).
- Directive 2002/46/EC on food supplements, consolidated text, Articles 2 and 6. European Union, 2002 (consolidated 2017).
- Regulation (EC) No 178/2002, general food law, Article 2 definition of food. European Union, 2002 (consolidated 2024).
- Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, Articles 2, 10 and 14. European Union, 2006 (consolidated 2014).
- Commission Regulation (EU) No 432/2012 establishing the list of permitted health claims, melatonin entries. European Commission, 2012.
- Commission Regulation (EU) 2022/860 amending Annex III to Regulation (EC) No 1925/2006 as regards monacolins from red yeast rice. European Commission, 2022.
- Judgment of the Court of Justice of 15 November 2007, Case C-319/05, Commission v Germany (garlic preparation in capsule form). Court of Justice of the European Union, 2007.
- Judgment of the Court of Justice of 15 January 2009, Case C-140/07, Hecht-Pharma GmbH v Staatliches Gewerbeaufsichtsamt Lüneburg. Court of Justice of the European Union, 2009.
- Judgment of the Court of Justice of 9 June 2005, Joined Cases C-211/03, C-299/03 and C-316/03 to C-318/03, HLH Warenvertrieb and Orthica. Court of Justice of the European Union, 2005.
- Herbal medicinal products, regulatory pathways including traditional use registration. European Medicines Agency.
- Circadin (melatonin), European public assessment report. European Medicines Agency.
- Food supplements. European Commission, Directorate-General for Health and Food Safety.
- Bilia AR, Bergonzi MC. Medicinal plants and their preparations in the European market: why has the harmonization failed? Phytomedicine. 2021;81:153421. PMID 33291029.
